Table 1.
Demographic, virological, and immunological characterization of study participants.
| RHI-LVL (N = 14) | RHI-HVL (N = 6) | LTNPs (N = 12) | Progressors (N = 12) | Healthy controls (N = 20) | |
|---|---|---|---|---|---|
| (Median and range) | |||||
| Age (years) | 28 (16–35) | 26 (23–33) | 31 (29–34) | 38 (27–45) | 28 (23–34) |
| Gender [female (F): male (M)] | F:12 and M:2 | F:4 and M:2 | F:8:M:4 | F:6:M:5 | F:13 and M:7 |
| CD4 count (cells/mm3) | 574 (280–1211) | 569 (116–743) | 695 (476–1069) | 111 (26–156) | 976 (403–1398) |
| Time after infection | 180 days (75–308) | 102 days (25–285) | 9 years (8–14) | NA | NA |
| VL set point (RNA copies/ml) | 4774 (400–10143) | 34957 (13389–228397) | NA | NA | NA |
| Viral load at enrollment (RNA copies/ml) | 1830 (400–61400) | 33950 (16300–55000) | 2561 (undetectable–6890) | 184137 (18012–482236) | NA |